Titlebook: Recent Advances in Cell Biology of Acute Leukemia; Impact on Clinical D Wolf-Dieter Ludwig,Eckhard Thiel Conference proceedings 1993 Spring

adhesive

Molecular Cytogenetic Applications in Leukemiasmatologic neoplasms. The fact that leukemia’s and lymphomas are heterogeneous regarding involvement of various bone marrow cell lineages renders standard cytogenetic analysis less than ideal, as it does not allow the study of cell lineage. The recently developed chromosome-specific probes and their

分發(fā)

代理人

DNA Aneuploidy in Childhood Acute Lymphoblastic Leukemia: Relation to Clinical Determinants and Progom empirically designed treatment concepts (Riehm et al. 1980, 1990). Recent attempts to further improve the outcome in children with this disease have concentrated on unraveling the underlying pathogenetic mechanisms. They have provided the means to discriminate subgroups of patients with different

NEEDY

exceptional

colostrum

Molecular Genetic Techniques for Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemes a significant clinical problem (Champlin and Gale 1989). Since most recurrences originate from neoplastic cells escaping the therapeutic intervention, the development of methods to monitor individual responses of patients, to detect impending relapses prior to clinical manifestation, or to determ

Antioxidant

periodontitis

Detection of Aberrant Antigen Expression in Acute Myeloid Leukemia by Multiparameter Flow Cytometryblastic (ALL) and acute myeloid leukemia (AML) is supported by cytochemistry and is well reproducible between experienced hematologists and/or pathologists (Bennett et al. 1976; MIC Classification 1988). Disagreement can arise within the myeloid lineage, e.g. in the distinction of “de novo” and “sec

陶醉

Detection of Residual Leukemic Cells in Adult Acute Lymphoblastic Leukemia by Analysis of Gene Rearrade by intensive chemotherapy. Today, more than 75% of the patients attain a CR (Hoelzer et al. 1984; Clarkson et al. 1985; Jacobs and Gale 1984). Nevertheless, the recurrence rate remains high. Only about 40% of patients are still alive and in CR after 5 years (Hoelzer et al. 1984; Clarkson et al.

Confess

Interleukin-2-Based Immunotherapy in the Management of Minimal Residual Disease in Acute Leukemia Pability of exploiting interleukin-2 (IL-2), with or without ex vivo activated lymphokine activated killer (LAK) cells, as an immunotherapeutic tool in the treatment of solid tumor patients has over the last 5–6 years become a new and promising reality in the management of cancer (Rosenberg et al. 198